Literature DB >> 2834998

Toxicity trial of prophylactic 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine (ganciclovir) after marrow transplantation in dogs.

F R Appelbaum1, J D Meyers, H J Deeg, T Graham, F Schuening, R Storb.   

Abstract

The effects of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine, or ganciclovir, administered during the immediate posttransplant period to dogs given total-body irradiation and autologous marrow transplants were studied. Doses of ganciclovir of 3.0 mg/kg (body weight) per day were well tolerated without detectable delay in hematopoietic recovery, whereas doses of 5.0 mg/kg per day were associated with delayed platelet recovery.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2834998      PMCID： PMC172151          DOI： 10.1128/AAC.32.2.271

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Marrow infusions in dogs given midlethal or lethal irradiation.

Authors:  E D Thomas; R LeBlond; T Graham; R Storb
Journal:  Radiat Res       Date:  1970-01       Impact factor: 2.841

2.  Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts.

Authors:  A Erice; M C Jordan; B A Chace; C Fletcher; B J Chinnock; H H Balfour
Journal:  JAMA       Date:  1987-06-12       Impact factor: 56.272

3.  Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men.

Authors:  H Masur; H C Lane; A Palestine; P D Smith; J Manischewitz; G Stevens; L Fujikawa; A M Macher; R Nussenblatt; B Baird
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

4.  Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates.

Authors:  H J Deeg; R Storb; F R Appelbaum; M S Kennedy; T C Graham; E D Thomas
Journal:  Transplantation       Date:  1984-01       Impact factor: 4.939

5.  Effect of trimethoprim-sulfamethoxazole on hematological recovery after total body irradiation and autologous marrow infusion in dogs.

Authors:  H J Deeg; J D Meyers; R Storb; T C Graham; P L Weiden
Journal:  Transplantation       Date:  1979-09       Impact factor: 4.939

6.  Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine.

Authors:  D Felsenstein; D J D'Amico; M S Hirsch; D A Neumeyer; D M Cederberg; P de Miranda; R T Schooley
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

7.  Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro.

Authors:  E C Mar; Y C Cheng; E S Huang
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

8.  Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia.

Authors:  D H Shepp; P S Dandliker; P de Miranda; T C Burnette; D M Cederberg; L E Kirk; J D Meyers
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

9.  9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent.

Authors:  J C Martin; C A Dvorak; D F Smee; T R Matthews; J P Verheyden
Journal:  J Med Chem       Date:  1983-05       Impact factor: 7.446

10.  9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication.

Authors:  A K Field; M E Davies; C DeWitt; H C Perry; R Liou; J Germershausen; J D Karkas; W T Ashton; D B Johnston; R L Tolman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205
View more
  3 in total

Review 1.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

2.  Screening of antimicrobial agents for in vitro radiation protection and mitigation capacity, including those used in supportive care regimens for bone marrow transplant recipients.

Authors:  Michael W Epperly; Darcy Franicola; Donna Shields; Jean-Claude Rwigema; Brandon Stone; Xichen Zhang; William McBride; George Georges; Peter Wipf; Joel S Greenberger
Journal:  In Vivo       Date:  2010 Jan-Feb       Impact factor: 2.155

3.  Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication.

Authors:  George W Koszalka; Nelson W Johnson; Steven S Good; Leslie Boyd; Stanley C Chamberlain; Leroy B Townsend; John C Drach; Karen K Biron
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.